Protease-activated receptors (PARs) are a unique family of G-protein coupled receptors. PAR4, a member of PARs family, was reported to be related to the development of cancers. Whether PAR4 plays a role in the progress of esophageal squamous cancer is unknown. In this study, differential expression of PAR4 in esophageal squamous cancer was measured by real-time PCR (n = 28), western blot and tissue microarrays (n = 78). The results showed that PAR4 expression was remarkably decreased in esophageal squamous cancer tissues compared with the matched noncancerous tissues, especially in low differentiation and positive distant metastasis carcinoma tissues. Furthermore, the methylation level of PAR4 promoter in esophageal cancer cells and normal epithelial cells was determined. Human esophageal cancer cells TE-1 displayed significant hypermethylation of 19 CpG sites, but pronounced hypomethylation of the sites in esophageal epithelial cells HEEpiC. The results suggested that down-regulation expression of PAR4 occurs frequently in esophageal squamous cancers, and the loss of PAR4 expression may partly result from hypermethylation of the PAR4 promoter. That PAR4 expression difference in tumor progression possibly makes PAR4 become a molecular mark of tumor diagnosis.
Protease-activated receptors (PARs) are a unique family of G-protein coupled receptors (GPCRs) [1] . Four members have been cloned in human, namely, PAR1, PAR2, PAR3, PAR4, sharing the common mechanism of activation by proteolysis [2] . PAR4 differential expression occurs in many malignant tumors, such as gastric cancer, liver cancer, colon cancer, lung cancer, breast cancer and prostate cancer [3] . Some studies revealed that PAR4 is highly expressed in colon cancer and liver cancer cells, and PAR4 induces the proliferation and migration of cancer cells [4, 5] . Other research revealed that PAR4 is lowexpressed in gastric carcinoma and even no expression in some poor-differentiated and high in gastric cancer with lymph node metastases [6] . However, the differential expression of PAR4 in esophageal cancer has not been investigated.
Esophageal squamous cell carcinoma (ESCC), accounting for around 90% of esophageal cancers, is the major histological form of esophageal cancer in East Asian countries [7] . Due to the difficulties in early diagnosis and treatment, ESCC becomes a highly aggressive malignancy with a poor prognosis [8] . Thus it is important to find a potentially useful and early diagnostic and treatment indicator. An association between PARs and esophageal cancer has been implicated. PAR1 was positive expressed in 68.2% esophageal cancer tissues, while no significant expression in normal esophageal squamous epithelium. And PAR1 overexpression was significantly associated with tumor node metastasis (TNM) stage and regional lymph node involvement [9] . Similarly, PAR2 expression was increased in primary esophageal squamous cell carcinoma compared with the normal esophageal epithelial cell. And PAR2 expression level in tumor tissues was significantly correlated with the clinical stage, histological grade and prognosis [10] . But it is still not clear about the molecular mechanism underlying the progression of esophageal cancer.
In this study, we discussed the differential expression of PAR4 in esophageal squamous cell carcinoma. And the results showed that the expression of PAR4 is reduced in esophageal squamous cancer tissues, and the down-regulation expression was partly resulted from the increased methylation level of PAR4 promoter. examined in parallel as an internal control. The identity of the PCR products was confirmed by DNA sequencing. Each sample was run three times. No template controls (no cDNA in PCR) were run to detect unspecific or genomic amplification and primer dimerization. Fluorescence curve analysis was carried using Opticon Monitor software. Relative quantitative evaluation of PAR4 levels were performed by E-method and expressed as a ratio of the transcript of PAR4 to GAPDH in the tumor tissue divided by a similar ratio in the non-neoplastic tissue of the same patient [13] .
Tissue immunohistochemistry. Tissue immunohistochemistry was performed as described previously [4] . Briefly, antigen retrieval was performed by heating in an autoclave at 121°C for 5 min. Dewaxed sections were pre-incubated with blocking serum and then incubated overnight with the anti-human PAR4 antibody (C-20, 1:1200; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C. Specific binding was detected by a streptavidin-biotin-peroxidase assay kit (Maxim, Fujian, China). The section was counterstained with Harris hematoxylin. Direct microscopic micrographs were captured using a Leica DFC320 camera controlled by Leica IM50 software (Leica, Germany). Sections incubated with normal goat IgG were served as a negative control and the negative immunohistochemical control was devoid of any detectable immunolabeling. Specificity of the antibodies for PAR4 was confirmed by pre-incubation overnight at 4°C with its respective antigen (Santa Cruz) in a 20-fold molar excess of antigen to antibody. Pre-incubation with PAR4 antigen resulted in an absence of immunolabeling.
Immunohistochemical staining was assessed semiquantitatively by measuring both the intensity of the staining (0, 1, 2, or 3) and extent of staining (0, 0%; 1, 0-10%; 2, 10-50%; 3, 50-100%). The scores for the intensity and extent of staining were multiplied to give a weighted score for each case (maximum possible, 9). For the statistical analysis, the weighted scores were grouped into two categories where scores of 0-3 were considered negative and 4-9 positive [14] .
Western blotting. Tissue samples were homogenized in radioimmunoprecipitation assay buffer (Sigma) with protease inhibitors cocktail (Sigma). The protein concentration was determined by a protein assay kit (Bio-Rad). Samples (containing 50 µg of protein) were loaded on an SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gel and then electro-transferred onto a PVDF membrane. The membrane was subsequently blocked with 3% bovine serum albumin (BSA) and incubated with anti-PAR4-antibody (C-20, 1:3500, 4°C, overnight) and relative secondary antibody. Protein bands were visualized with Super Signal reagents (Pierce, Rockford, IL, USA). Specificity of the anti-PAR4 antibody was confirmed by pre-incubation with its antigenic peptide in a 20-fold molar excess of antigen to antibody. Preincubation with PAR4 antigen resulted in an absence of PAR4 band.
Bisulfite sequencing. Genomic DNA from cell lines was isolated with the Universal Genomic DNA Extraction Kit (TaKaRa) and bisulfiteconverted using the Clontech EpiXplore TM Methyl Detection Kit (TaKaRa). PAR4 promoter sequences were amplified from bisulfite-converted DNA by PCR, purified from agarose gels and subcloned into the pBackZero T Vector (TaKaRa). For each sample, 11 individual clones were sequenced to identify methylated cytosine residues. PCR primer sequences (forward and reverse) were 5' -TTTAAGGGTGATTTTAGGAAAGGTTTAGAG-3' and 5'-ACTATAACCTCAAACTTCCTACCTC-3' .
Statistical analysis.
All statistical analyses were performed by the SPSS 11.0 software (SPSS Inc., Chicago, IL, USA). The Fisher's exact test and chi squared test for the significance of correlations between PAR4 expression and clinicopathological parameters (Tables 1 and 2 ). Differences in the numerical data between the two paired groups were evaluated using the paired Wilcoxon test (Fig. 2) . The level of statistical significance was set at the level of p < 0.05.
Results
PAR4 mRNA was down-regulated frequently in esophageal squamous cancers and the correlation with clinicopathological parameters. As shown in Fig.1 , RT-PCR was performed on matched normal and cancer tissue specimens of 3 patients selected randomly (n = 3). The results showed that mRNA levels of PAR4 in cancer were significantly decreased compared to relative normal tissues after the samples were normalized to GAPDH levels. And PAR4 expression was also decreased in esophageal cancer cell line TE-1 compared to normal esophageal epithelial cell HEEpiC.
The differential expression of PAR4 mRNA was further examined by real-time PCR analysis in 28 esophageal squamous cancer tissue samples. We compared the primary tumor with the matched non-neoplastic tissues. Overall down-regulated PAR4 expression was detected in 68% (19 of 28) of esophageal cancer tissues. PAR4 mRNA was reduced 14.7 ± 3.5 fold (mean ± SEM) in esophageal squamous cancers (p = 0.001, paired 1 " was defined as "decreased", and " ≤2 1 " was "not decreased" (Fig. 2A) . Next we investigated the clinical significance of loss of PAR4 expression on clinic-pathological data. There only existed significant differences of PAR4 mRNA expression in poor-differentiated tumors versus well-/moderated-differentiated tumors (p = 0.036, chi squared test) ( Table 1 ). In details, PAR4 mRNA was reduced 29.33 ± 6.4 fold (mean ± SEM) in 11 poor-differentiated cancers (p = 0.001, paired Wilcoxon test) and 5.31 ± 1.6 fold (p = 0.0003) in 17 well-/moderateddifferentiated cancers (Fig. 2B) .
Protein levels of PAR4 were frequently decreased in the esophageal cancer tissues and the correlation with histopathologic features. Using Western blotting, we found that PAR4 expression was reduced significantly in esophageal cancer comparing with the matched nonmalignant esophageal tissue. PAR4 down-regulation expression was also observed in esophageal cancer cell line TE-1, while the protein expression was high in human esophageal epithelial cell HEEpiC (Fig. 3) We further used immunohistochemical assay to assess the in vivo status of PAR4 expression in esophageal squamous cancerous and normal tissues. PAR4 was expressed at high level in non-neoplastic esophageal squamous epithelial cells (Fig. 4A) . However, in cancerous tissue, PAR4 expression was significantly reduced and even lost. In details, PAR4 was mainly stained in well-differentiated esophageal cancers cells (Fig. 4B) , low-expressed in the moderate-differentiated esophageal cancers cells (Fig. 4C) , and even no expression in the poor-differentiated esophageal cancers (Fig. 4D) , suggesting PAR4 expression was related to the progress of esophageal squamous cancers. Next, we investigated the correlation between loss of PAR4 expression and clinicpathological parameters. PAR4 expression was decreased in 70% (55 of 78) of esophageal squamous cancer tissues. And PAR4 down-regulation expression was associated with tumor differentiation and distant metastasis. In details, PAR4 expression was decreased in 90% of poor-differentiated cancers and in 63% of well-/moderated-differentiated cancers (p = 0.013, chi squared test); PAR4 expression was decreased in 100% of distant metastasis cancers, and in 67% of no distant metastasis cancers (p = 0.039, chi squared test) ( Table 2 ).
Analysis of the methylation level of promoter region of PAR4 gene in esophageal cancer cell. Using the genomic bisulfite sequencing method, we analyzed 19 CpG sites of PAR4 gene in human esophageal epithelial cell line HEEpiC and human esophageal cancer cell line TE-1. TE-1 cells displayed hypermethylation of the 19 CpG sites, and the total methylation rate is 94.7%. However, the total methylation rate of PAR4 is 35.4% in 19 CpG sites of HEEpiC cells, which showed pronounced promoter hypomethylation compared with the esophageal cancer cell (Fig. 5) , suggested PAR4 down-regulated expression possibly resulted from the hypermethylation of gene promoter region. 
Discussion
PARs have been demonstrated to be implicated in tumor growth, invasion and metastasis in several malignancies [15] . PAR1, widely expressed in human cancers, promotes the transformation and adhesion of pancreatic cancer cells as well as the invasion and metastasis of oral adenocarcinoma, colon cancer and breast cancer cells [16] [17] [18] . PAR2 is closely related to the growth and invasion of nasopharyngeal cancer, breast cancer, gastric cancer, colon cancer, prostate cancer and pancreatic cancer [19] [20] [21] . In fact, PAR1 and PAR2 were implicated to be overexpressed in the progress of ESCC, and the expression level serves as the possible prognostic marker only because the protein high expression strong correlates with tumor stage [22, 23] . The role of PAR3 and PAR4 in cancer development is not clear. The latest research shows that PAR4 expression was remarkably decreased in gastric cancer tissues as compared with the matched noncancerous tissues, especially in positive lymph node or low differentiated cancers [6] . Jiang et.al reported that PAR4 down-regulation expression was found in lung adenocarcinoma and PAR4 decreased expression was associated with a more clinically aggressive phenotype, suggesting that PAR4 may act as a tumor suppressor in lung adenocarcinoma [24] . However, PAR4 was over-expressed in colorectal cancer [25] and liver cancer [20] , and the up-regulation expression of PAR4 contributed to the proliferation of cancer cells [26] . Further, PAR4 agonists can induce calcium influx and promote the proliferation of colon cancer cells through ErbB2 transcriptional activation and Src kinase pathway [26] . The results indicated that PAR4 plays different roles in progression of different cancers. In our research, we firstly presented some fundamental data about PAR4 expression in esophageal squamous cancer. PAR4 expression was decreased frequently in esophageal squamous cancer using RT-PCR, real-time PCR, Western blotting, and the immunohistochemical assays. And PAR4 decreased expression was related to cell differentiation and positive distant metastasis. Esophageal squamous cancer is one of the least studied and deadliest cancers worldwide because of fast progress, easy metastasis and poor prognosis [27] , and its histological grade determines its diagnosis, treatment and survival rate [28] . In this study, we noted that PAR4 reduced expression and even no expression was found in the advanced esophageal cancer, such as poor-differentiated cancers and positive distant metastasis cancers, indicating that PAR4 plays tumor suppressing role in the development of esophageal squamous cancer. And real-time PCR and immunostaining results showed that there exists significant correlation between PAR4 down-regulation expression and tumor poor-differentiation; Similarly immunostaining results also revealed the significant correlation between PAR4 down-regulated expression and distant metastasis, while real-time PCR didn't show the significance. The inconsistent results possibly resulted from the different tissue samples and the less number of tissues analyzed by real-time PCR. In brief, PAR4 might be a potential marker for esophageal squamous carcinoma diagnosis and treatment.
The phenotype of cancerous cell may arise either from genetic sequence mutations that disrupt gene function or epigenetic events that may alter the heritable state of gene expression [29] . The main epigenetic modification of genome is methylation of cytosine residues within the context of 'CpG islands' in the promoter regions, which will lead to transcriptional silencing through a complex process involving histone deacetylation and chromatin condensation, and finally results to lost of gene expression [30] . And the alterations in DNA methylation level are a fundamental molecular change associated with the neoplastic process and have important biologic implications for tumor initiation and progression [31] . In our previous study, we found that PAR4 expression was decreased in the gastric carcinoma, and the down-regulation expression was partly resulted from the hypermethylation of CpG sites in gene promoter region [6] . Interestingly, at the present study, we found that the promoter CpG sites were hypermethylated in esophageal cancer cell TE-1 with decreased PAR4 expression, while the CpG sites were hypomethylated of promoter in normal esophageal epithelial cell HEEpiC with PAR4 high-level expression. These results indicated that the down-regulation expression of PAR4 in esophageal squamous was partly resulted from the hypermethylation of CpG sites in gene promoter region.
In conclusion, we show that PAR4 is frequently downregulated in esophageal squamous cancer and the decreased expression was associated with tumor differentiation and distant metastasis. Further the aberrant DNA methylation of promoter CpG sites is possibly a mechanism of PAR4 downregulation expression. These results might provide valuable insights for understanding molecular mechanism of carcinogenesis, progression and metastasis of esophageal cancer.
